QUOTE AND NEWS
TheStreet.com  Sep 30  Comment 
NEW YORK (TheStreet) -- Analysts were divided on the outlook for drug maker Seattle Genetics after the company yesterday reported positive top-line results for a trial of its Hodgkin lymphoma treatment Adcetris, but noted that the drug did not...
TheStreet.com  Sep 30  Comment 
NEW YORK (TheStreet) -- Shares ofaSeattle Geneticsa fell 5.29% to $36.36 in morning trading Tuesday afteraBank of America/Merrill Lyncha downgraded the stock to "underperform" from "neutral." The firm saidaAethera data was not as positive as...
Benzinga  Sep 30  Comment 
Benzinga  Sep 30  Comment 
Analysts at Bank of America downgraded Seattle Genetics (NASDAQ: SGEN) from Neutral to Underperform. The target price for Seattle Genetics has been lowered from $ $40 to $34. Seattle Genetics shares have dropped 14.48% over the past 52...
TheStreet.com  Sep 29  Comment 
SEATTLE (TheStreet) -- Seattle Genetics will seek to expand theaapproved use of its Hodgkin lymphomaadrug Adcetris following positive results from a phase III study, the company announced Monday. In the study (known as AETHERA), treatment...
DailyFinance  Sep 29  Comment 
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that patients with Hodgkin lymphoma (HL) who received ADCETRIS (brentuximab vedotin) as consolidation therapy...
Benzinga  Sep 24  Comment 
Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted ADCETRIS (brentuximab vedotin) data to be presented at the 2014 European Society for Medical Oncology (ESMO) Congress being held September 26-30, 2014 in Madrid, Spain. The data include a...
newratings.com  Sep 10  Comment 
WASHINGTON (dpa-AFX) - Seattle Genetics Inc (SGEN) and Genmab A/S (GNMSF.PK) on Wednesday entered into an additional antibody-drug conjugate collaboration. Under the new agreement, Genmab will pay an upfront fee of $11 million for exclusive...
SeekingAlpha  Aug 19  Comment 
By Stephen Simpson, CFA: Oncology biotech Seattle Genetics (NASDAQ:SGEN) has had a bit of an interesting ride since I reviewed the company's prospects and valuation back in December. The shares moved up about 40% through February of this year on...
newratings.com  Aug 12  Comment 
WASHINGTON (dpa-AFX) - Seattle Genetics Inc. (SGEN) announced Tuesday that it has initiated a phase 1 clinical trial evaluating SGN-CD70A for CD70-positive relapsed or refractory non-Hodgkin lymphoma or NHL and metastatic renal cell carcinoma or...
Market Intelligence Center  Aug 7  Comment 
Wednesday’s trading in Seattle Genetics Inc. (SGEN) gives options traders an opportunity for a 11.75% return. By selling the Dec. '14 $37.00 call and buying the Jan. '16 call at the $17.50 level for a net debit of $17.45, traders will book a...




 

Seattle Genetics, Inc. is a biotechnology company developing monoclonal antibody-based therapies for treating cancer and autoimmune disease.[1] The company is working to develop next generation monoclonal therapies called antibody-drug conjugates (ADCs). The technology links potent synthetic drugs with monoclonal antibodies. The company has collaborations with major industry players all over the world such as: Millennium Pharmaceuticals, Bayer AG (BAYRY), Celldex Therapeutic (BER:TCE1), GlaxoSmithKline (GSK), Genentech (DNA), and quite a few others.[1] Leveraging these collaborations the company is working to navigate the high development costs and regulations that are indicative of the drug industry.

Business Growth

Seattle Genetics does not have any commercial products yet, but had revenue of $107.5 million for 2010. This was an increase of 107% from 2009. The company derived its revenue from payments that included technology access and maintenance fees, milestone and reimbursement payments from its collaborations. Its large jump from 2009 was primarily due to payments received from its collaborations with Genentech, Millennium, and other ADC collaborations.[1]

Trends and Forces

High Costs of Drug Development make it Difficult for Small Companies like Seattle Genetics

For more detailed information on the FDA approval process, see also Clinical trials.

Developing a new drug is a time-consuming and costly endeavor. Hundreds of thousands of candidate compounds must be screened to identify a handful of potential drugs, and even fewer of these candidate drugs are found to be effective at treating a disease. The drug must then pass strict safety standards in several series of clinical trials. The entire process of developing a new drug and bringing it to the market takes up to 10 to 15 years and on average costs $1.3 billion.[2]

Tightening Food and Drug Administration (FDA) Regulations

Beginning in 2009, the FDA implemented a series of reforms that include stricter monitoring of drug adverse events, more funding for the agency, stronger ability to force product recalls, more scientific expertise within the agency, more transparency. Even before 2009 the result has been a much more conservative FDA, demanding more product information.[3]

Competition

The various aspects of patent protection and the extremely high costs of researching and developing drugs marks the pharmaceutical industry with high risk and high competitiveness. It is important to keep in mind when considering a comparison of industry players that competition does not arise between each company as a whole, but rather between specific drug areas and their relative advantages in therapeutic treatment. Due to this fact many of Seattle Genetic's collaborators are competitors since they are developing therapies in similar disease areas. They include:

References

  1. 1.0 1.1 1.2 Seattle Genetics 2010 10k
  2. DiMasi, Joseph, “The Cost of Biopharmaceutical R&D: Is Biotech Different?,” Managerial and Decision Economics, 2007
  3. The FDA: A tough tonic
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki